Citius Pharmaceuticals, Inc. (CTXR) Financials
CTXR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 97.4 million | 12.1 million |
2023-09-30 | 103.6 million | 12.2 million |
2023-06-30 | 110.4 million | 12.1 million |
2023-03-31 | 104.2 million | 12.4 million |
CTXR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -6.1 million | 3.1 million |
2023-09-30 | -6.8 million | 3.1 million |
2023-06-30 | -9.6 million | 1.2 million |
2023-03-31 | -7.9 million | 1.2 million |
CTXR Net Income
No data available :(
CTXR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 20.3 million | - | 428569 |
2023-09-30 | 26.5 million | - | 481245 |
2023-06-30 | 33.3 million | - | 532882 |
2023-03-31 | 29.1 million | - | 582302 |
CTXR Shares Outstanding
CTXR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 2.6 million | 6.7 million | - |
2023-09-30 | - | 2.9 million | 7.2 million | - |
2023-06-30 | - | 3.8 million | 4.9 million | - |
2023-03-31 | - | 4.7 million | 6.0 million | - |
CTXR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | - | 51008 |
2023-09-30 | - | 49969 |
2023-06-30 | - | 49017 |
2023-03-31 | - | 48143 |
CTXR
Price: $0.70
52 week price:
Earnings Per Share: -0.26 USD
P/E Ratio: -3.83
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 674400
Ebitda: -9.5 millionMarket Capitalization: 121.9 million